Download PDF
Pharmacopsychiatry 2015; 48(03): 111-117
DOI: 10.1055/s-0035-1545300
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Association of the Choline Acetyltransferase Gene with Responsiveness to Acetylcholinesterase Inhibitors in Alzheimer’s Disease

H. Yoon   *
1   Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
W. Myung   *
1   Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
S.-W. Lim
2   Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Korea
3   SAIHST, Sungkyunkwan University School of Medicine, Seoul, Korea
,
H. S. Kang
2   Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Korea
,
S. Kim
4   Biostatistics Team, Samsung Biomedical Research Institute, Seoul, Korea
,
H.-H. Won
2   Center for Clinical Research, Samsung Biomedical Research Institute, Seoul, Korea
,
B. J. Carroll
5   Pacific Behavioral Research Foundation, Carmel, CA, USA
,
D. K. Kim
1   Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
› Author Affiliations
Further Information

Publication History

received 14 July 2014
revised 23 December 2014

accepted 19 January 2015

Publication Date:
02 March 2015 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction: The response to acetylcholinesterase inhibitors (AChEIs) of Alzheimer’s disease (AD) patients varies depending on the genetic characteristics of the patient. We have examined the association of response to AChEIs and genetic polymorphisms in AD patients.

Methods: 158 patients with AD underwent treatment with AChEIs, and the therapeutic effect was assessed with the Korean version of the Mini Mental State Examination (K-MMSE). The association of 25 SNPs located in 3 genes (CHAT, CHT and ACHE) with changes in the K-MMSE score was analyzed.

Results: The response to AChEIs in AD patients was significantly associated with 2 SNPs on the intronic region of CHAT rs2177370 (uncorrected P=0.0025, FDR controlled P=0.026) and rs3793790 (uncorrected P=0.0024, FDR controlled P=0.026).

Conclusion: The results of our study confirmed again that genetic polymorphism of CHAT has an influence on drug response in AD.

Key words

Alzheimer’s disease - acetylcholinesterase inhibitors - drug response - CHAT

* These individuals contributed equally to this article as co-first authors


 

  • References

  • 1 Kawas CH, Brookmeyer R. Aging and the public health effects of dementia. N Engl J Med 2001; 344: 1160-1161
    CrossrefPubMedGoogle Scholar
  • 2 Ballard C, Gauthier S, Corbett A et al Alzheimer’s disease. Lancet 2011; 377: 1019-1031
    CrossrefPubMedGoogle Scholar
  • 3 Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6: S3-S18
    CrossrefPubMedGoogle Scholar
  • 4 Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 2005; 105: 145-158
    PubMedGoogle Scholar
  • 5 Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-739
    CrossrefPubMedGoogle Scholar
  • 6 Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011; 13: 987-995
    CrossrefPubMedGoogle Scholar
  • 7 Bizzarro A, Marra C, Acciarri A et al Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20: 254-261
    CrossrefPubMedGoogle Scholar
  • 8 Choi SH, Kim SY, Na HR et al Effect of ApoE genotype on response to donepezil in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 25: 445-450
    CrossrefPubMedGoogle Scholar
  • 9 Rigaud AS, Traykov L, Latour F et al Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics 2002; 12: 415-420
    CrossrefPubMedGoogle Scholar
  • 10 Harold D, Macgregor S, Patterson CE et al A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacogenet Genomics 2006; 16: 75-77
    CrossrefPubMedGoogle Scholar
  • 11 Scacchi R, Gambina G, Moretto G et al Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 502-507
    CrossrefPubMedGoogle Scholar
  • 12 Brandon EP, Mellott T, Pizzo DP et al Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J Neurosci 2004; 24: 5459-5466
    CrossrefPubMedGoogle Scholar
  • 13 McKhann G, Drachman D, Folstein M et al Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-944
    CrossrefPubMedGoogle Scholar
  • 14 Han C, Jo SA, Jo I et al An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: demographic influence and population-based norms (the AGE study). Arch Gerontol Geriatr 2008; 47: 302-310
    CrossrefPubMedGoogle Scholar
  • 15 de Bakker PI, Yelensky R, Pe’er I et al Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217-1223
    CrossrefPubMedGoogle Scholar
  • 16 Kang YW, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination in dementia patients. J Korean Neurol Assoc 1997; 15: 300-308
    PubMedGoogle Scholar
  • 17 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
    CrossrefPubMedGoogle Scholar
  • 18 Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414
    PubMedGoogle Scholar
  • 19 Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7: 781-791
    CrossrefPubMedGoogle Scholar
  • 20 Schaid DJ, Jacobsen SJ. Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol 1999; 149: 706-711
    CrossrefPubMedGoogle Scholar
  • 21 Barrett JC, Fry B, Maller J et al Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
    CrossrefPubMedGoogle Scholar
  • 22 Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169
    CrossrefPubMedGoogle Scholar
  • 23 Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445
    CrossrefPubMedGoogle Scholar
  • 24 Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-514
    PubMedGoogle Scholar
  • 25 Grunblatt E, Reif A, Jungwirth S et al Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer’s disease: the VITA and Milano studies. J Psychiatr Res 2011; 45: 1250-1256
    CrossrefPubMedGoogle Scholar
  • 26 Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 2013; 36: 375-399
    CrossrefPubMedGoogle Scholar
  • 27 Lee JJ, Jo SA, Park JH et al Choline acetyltransferase 2384 G>a polymorphism and the risk of Alzheimer’s disease. Alzheimer Dis Assoc Disord 2012; 26: 81-87
    CrossrefPubMedGoogle Scholar
  • 28 Myung W, Lim SW, Kim S et al Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 2013; 225: 283-290
    CrossrefPubMedGoogle Scholar